fqubed Concludes Technology Licensing Agreement with Pharmacopeia
SAN DIEGO, April 12 /PRNewswire/ -- fqubed today announced execution of a
license contract with Pharmacopeia Inc. . Under the terms of the agreement
fqubed has been granted a worldwide license, exclusive in fqubed's areas of
business interest, to the intellectual property claimed in two issued
Pharmacopeia patents. fqubed has also acquired from Pharmacopeia two high
throughput experimentation instruments that embody certain of the patented
claims. The technology integrates multiplexed fluid dispensing through a novel
valveless delivery system, fluid processing, and automated soft materials
product collection. Originally invented to streamline a solvent processing step
in Pharmacopeia's discovery chemistry workflow, fqubed has identified a number
of other application possibilities. The terms of the license agreement include
payments to Pharmacopeia of a license issuance fee and royalties on both sales
of systems and applications in services collaborations.
fqubed intends both to modify and to further develop the licensed technology,
internally and in development collaborations with partners. While other details
of fqubed's business aspirations for the technology remain under discussion, the
licensing terms allow sales of systems by fqubed, as well as application of
systems by fqubed in support of internal or partner projects.
"Pharmacopeia has developed a considerable intellectual property portfolio aswe
have built and developed our ECLiPS compound synthesis and uHTS platforms,"
notes Stephen A. Spearman, Ph.D., Chief Operating Officer of Pharmacopeia Drug
Discovery. "We are always interested in leveraging these assets through
relationships with innovative companies like fqubed, who we believe will be able
to build scientific and commercial value using our inventions in areas that are
beyond the scope of our own efforts." "fqubed's intellectual property portfolio derives from two main activities,"
explains Dr. John M. Newsam, fqubed's President and Managing Director. "Firstly,
we have executed license agreements with third parties, the present agreement
being the third of these that we have concluded to date. Secondly, we continue
to file for patent protection for lead inventions made by the fqubed team. The
team has filed nine patent applications to date, the first two of which have
recently been allowed by the US Patent Office. In addition to the slate of
capabilities that we maintain as internal trade- secret, these two external
activities are important components of our accumulating technology position." "Pharmacopeia has an impressive track record of sustained technology
innovation," said Dr. R. Dominic King-Smith, fqubed's VP of Business
Development. "We are pleased to have the opportunity to benefit from
Pharmacopeia's patented technologies. While the innovations that fqubed is
making in the development of novel drug delivery media differ from those in the
development of drug leads themselves, there are real opportunities for
cross-leveraging of technology developments. The high throughput experimentation
systems now covered by this license agreement are a good example of one of
these." About fqubed fqubed develops innovative soft materials as delivery media for underexploited
actives in health- and personal-care products. fqubed's business is founded on
proprietary high throughput experimentation and micro- & nano-structuring
systems, engagement by leading companies in the targeted market sectors, and
access to proprietary underexploited actives. fqubed is based in San Diego,
CA.
Contact for additional information on fqubed: Ms. Lane Logan, fqubed, 6330 Nancy Ridge Drive (Suite 107), San Diego CA
92121
Phone: +1-858-677-6732 Fax: +1-858-677-6737
E-mail: web: http://www.fqubed.com/ About Pharmacopeia, Inc. Pharmacopeia is a leader in enabling science and technology that accelerates and
improves the drug discovery and chemical development processes. Pharmacopeia's
Drug Discovery business integrates proprietary small molecule combinatorial and
medicinal chemistry, high throughput screening, in- vitro pharmacology,
computational methods and informatics to discover and optimize lead compounds. Pharmacopeia's software subsidiary, Accelrys, develops and commercializes
molecular modeling and simulation software for the life sciences and materials
research markets, cheminformatics and decision support systems, and
bioinformatics tools including gene sequence analysis. Accelrys consulting
services provides expert assistance in the configuration, implementation and
integration of a wide variety of software solutions to enable superior research
and discovery. Pharmacopeia is headquartered in Princeton, New Jersey.
Contact for additional information on Pharmacopeia, Inc.: Simon M. Tomlinson, Ph.D., Senior Vice President, Business Development
Pharmacopeia, Inc., PO Box 5350, Princeton, NJ 08543
Phone: +1 609 452-3600 Fax: +1 609 452 3672
E-mail: web: http://www.pharmacopeia.com/ When used anywhere in this document, the words "expects," "believes,"
"anticipates," "estimates" and similar expressions are intended to identify
forward-looking statements. Forward-looking statements herein may include
statements addressing future financial and operating results of Pharmacopeia. Pharmacopeia has based these forward-looking statements on its current
expectations about future events. Such statements are subject to risks and
uncertainties including, but not limited to, the successful implementation of
Pharmacopeia's strategic plans, the acceptance of new products, the obsolescence
of existing products, the resolution of existing and potential future patent
issues, additional competition, changes in economic conditions, and other risks
described in documents Pharmacopeia has filed with the Securities and Exchange
Commission, including its most recent report on Form 10-K and subsequent reports
on Form 10-Q. All forward-looking statements in this document are qualified
entirely by the cautionary statements included in this document and such
filings. These risks and uncertainties could cause actual results to differ
materially from results expressed or implied by forward-looking statements
contained in this document. These forward-looking statements speak only as of
the date of this document. Pharmacopeia disclaims any undertaking to publicly
update or revise any forward-looking statements contained herein to reflect any
change in its expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based. DATASOURCE: fqubed CONTACT: Ms. Lane Logan, fqubed, +1-858-677-6732, +1-858-677-6737, ; or Simon M. Tomlinson, Ph.D., Senior Vice President, Business Development, Pharmacopeia, Inc., +1-609-452-3600, Fax: +1-609-452-3672, Web site: http://www.pharmacopeia.com/ Web site: http://www.fqubed.com/
|